Williams A C, Browne S J, Manning A M, Daffada P, Collard T J, Paraskeva C
Department of Pathology and Microbiology, University of Bristol, School of Medical Sciences, UK.
Oncogene. 1994 May;9(5):1479-85.
Mutation of the p53 gene is thought to be a late event in human colorectal carcinogenesis, involved in the malignant conversion of the adenoma to the carcinoma. One of the questions that we hoped to address was whether, in vivo, a single mutational event in one p53 gene is sufficient to confer a significant growth advantage on a colonic epithelial cell. Such a growth advantage could result either from an increase in growth rate and/or loss of response to inhibitory growth signals naturally present in the colonic crypt. We therefore introduced the pC53-SCX3 143 (Val-Ala) p53 mutation into a non tumorigenic adenoma derived cell line, AA/C1, which contained a truncating APC mutation, activating K-ras mutation but was wild-type for the p53 protein. High levels of mutant p53 protein were detected in the pC53-SCX3 transfected AA/C1 cell lines but was found not to affect either the in vitro (colony forming efficiency, anchorage independence) or in vivo (tumorigenicity in nude mice) growth, when compared to vector control or the parental AA/C1 cell line. In addition, to test whether the cells become less sensitive to inhibitory growth factors, the response of the cell lines to the naturally occurring growth inhibitor TGF beta was also investigated. Even though TGF beta had previously been implicated in the control of growth of intestinal epithelium, expression of the mutant p53 protein did not affect the sensitivity of the parental AA/C1 cell line to TGF beta. Under the experimental conditions tested expression of the 143 (Val-Ala) p53 protein was unable to affect the in vitro or in vivo growth characteristics of the adenoma derived AA/C1 cell line. When compared to other studies, these results suggest that the genetic background of the individual recipient cell may greatly influence the effect of expression of a particular p53 mutation.
p53基因的突变被认为是人类结直肠癌发生过程中的晚期事件,参与腺瘤向癌的恶性转化。我们希望解决的问题之一是,在体内,一个p53基因中的单一突变事件是否足以赋予结肠上皮细胞显著的生长优势。这种生长优势可能源于生长速率的增加和/或对结肠隐窝中天然存在的抑制生长信号反应的丧失。因此,我们将pC53-SCX3 143(Val-Ala)p53突变引入一个非致瘤性腺瘤衍生细胞系AA/C1,该细胞系含有截短的APC突变、激活的K-ras突变,但p53蛋白为野生型。在pC53-SCX3转染的AA/C1细胞系中检测到高水平的突变型p53蛋白,但与载体对照或亲本AA/C1细胞系相比,发现其不影响体外(集落形成效率、不依赖贴壁生长)或体内(裸鼠致瘤性)生长。此外,为了测试细胞是否对抑制生长因子变得不敏感,还研究了细胞系对天然存在的生长抑制剂转化生长因子β(TGF-β)的反应。尽管TGF-β此前被认为参与肠道上皮生长的控制,但突变型p53蛋白的表达并未影响亲本AA/C1细胞系对TGF-β的敏感性。在所测试的实验条件下,143(Val-Ala)p53蛋白的表达无法影响腺瘤衍生的AA/C1细胞系的体外或体内生长特性。与其他研究相比,这些结果表明,单个受体细胞的遗传背景可能极大地影响特定p53突变表达的效果。